rectal lesion
Recently Published Documents


TOTAL DOCUMENTS

35
(FIVE YEARS 13)

H-INDEX

3
(FIVE YEARS 1)

2021 ◽  
pp. 1761-1767
Author(s):  
Makoto Saito ◽  
Shihori Tsukamoto ◽  
Takashi Ishio ◽  
Emi Yokoyama ◽  
Koh Izumiyama ◽  
...  

The standard treatment for colorectal mucosa-associated lymphoid tissue (MALT) lymphoma has not yet been established due to the rarity of the disease. Here, we report a case of long-term response to chemotherapy for colorectal MALT lymphoma (stage I). A 77-year-old frail female patient with diabetes mellitus and dementia developed melena of unknown etiology, and a colonoscopy was performed at a nearby hospital. A biopsy suggested malignant lymphoma, and she was referred to our department. As a result of re-examination of colonoscopy, a total of 3 submucosal tumor-like lesions were confirmed. Of these, a biopsy of the lesions in the ascending colon and rectum was performed, and MALT lymphoma was diagnosed on the basis of the histopathological findings. Following close examination, no other lymphoma lesions were found, and the patient was diagnosed with primary colorectal MALT lymphoma, stage I. After 1 course of R-THP-COP chemotherapy (rituximab + cyclophosphamide, pirarubicin, vincristine, and prednisone), the rectal lesion was confirmed to have almost disappeared endoscopically, and lymphoma cells were not found histopathologically. The patient was determined to be in complete remission (CR). However, due to hematological toxicity and a slight worsening of glucose control, the second chemotherapy course was changed to the BR regimen (rituximab + bendamustine), and 4 courses were performed (5 total courses of chemotherapy). Currently, >3 years have passed since reaching CR, and the patient is alive without recurrence.


2021 ◽  
Vol 44 (3) ◽  
pp. 98-100
Author(s):  
J Guilarte López-Mañas ◽  
F Valverde López ◽  
E Fernández
Keyword(s):  

Author(s):  
Montserrat Guraieb-Trueba ◽  
Juan Carlos Sánchez-Robles ◽  
Eduardo Navarro-Lara ◽  
Víctor Javier Herrera-Virrueta

Abstract Background Transanal minimally invasive surgery (TAMIS) is a surgical technique used for the excision of rectal neoplasia that gained popularity during the last decade.Due to the technical difficulty (non-articulated instruments, reduced workspace) and the long learning curve associated with this technique, the use of robotic platforms to improve resection results has been suggested and reported, at the same time that the learning curve decreases and the procedure is facilitated Materials and Methods From March 2017 to December 2019, all patients with rectal lesions eligible for TAMIS were offered the possibility to receive a robotic TAMIS (R-TAMIS). We used a transanal GelPoint Path (Applied Medical Inc., Santa Margarita, CA, USA) in the anal canal to be able to do the Da Vinci Si (Intuitive Surgical, Sunnyvale, CA, USA) robotic platform docking, which we used to perform the excision of the rectal lesion as well as the resection site defect. Results Five patients between 34 and 79 years of age underwent R-TAMIS. The mean distance to the anal verge was 8.8 cm. There were no conversions. The mean surgery time was 85 minutes, and the mean docking time was 6.6 minutes. Conclusions Robotic TAMIS is a feasible alternative to TAMIS, with a faster learning curve for experienced surgeons in transanal surgery and better ergonomics. Further studies are needed to assess the cost-benefit relationship.


2020 ◽  
Vol 75 (3) ◽  
Author(s):  
Francesco Coratti ◽  
Damiano Bisogni ◽  
Paolo Montanelli ◽  
Fabio Cianchi

2020 ◽  
Author(s):  
CC Rebelo ◽  
N Nunes ◽  
MF de Lima ◽  
DB Moura ◽  
JR Pereira ◽  
...  

2020 ◽  
Vol 64 (2) ◽  
pp. e25-e25
Author(s):  
Adam Studniarek ◽  
Jennifer Pan ◽  
Gerald Gantt ◽  
Anders Mellgren ◽  
Pier Cristoforo Giulianotti ◽  
...  

2019 ◽  
pp. 181-183
Author(s):  
Hariharanadha N Sarma ◽  
B Chaitanya ◽  
G Saiswaroop ◽  
Manu Goyal

Sign in / Sign up

Export Citation Format

Share Document